NVO Latest Headlines

TrumpRx expected to launch on Friday: report

at seekingalpha.com (Wed, 28-Jan 1:13 PM)

Novo Nordisk Is Spending Twice as Much as Eli Lilly (LLY) on Weight-Loss Drug Ads

at www.tipranks.com (Wed, 28-Jan 11:55 AM)

Novo ad spend for GLP-1s doubles that of Lilly in the U.S.: Reuters

at seekingalpha.com (Wed, 28-Jan 9:11 AM)

Novo advertising spend for GLP-1s doubles that of Lilly in the U.S.: Reuters

at seekingalpha.com (Wed, 28-Jan 9:11 AM)

Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline

at www.tipranks.com (Wed, 28-Jan 3:09 AM)

Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’

at www.tipranks.com (Mon, 26-Jan 10:30 AM)

Kepler Capital Sticks to Their Buy Rating for Novo Nordisk (0QIU)

at www.tipranks.com (Sat, 24-Jan 8:46 PM)

Novo sued for working with Teva to delay generic Victoza

at seekingalpha.com (Sat, 24-Jan 9:10 AM)

If NVO Price Stays Between $62 to $67 Level This Iron Condor Will Yield 54%

Market Chameleon (Fri, 23-Jan 11:47 AM)

Wegovy Pill Sets New Benchmark for Oral Weight Loss Treatment: Novo Nordisk’s Breakthrough Hits 70,000+ U.S. Pharmacies

Market Chameleon (Mon, 5-Jan 8:18 AM)

Novo Nordisk’s Higher-Dose Wegovy Shows 20.7% Average Weight Loss: Can This New Option Set a New Standard for Obesity Care?

Market Chameleon (Wed, 17-Dec 7:09 AM)

Novo Nordisk’s $10 Billion Bid for Metsera Tops Pfizer’s Offer, Setting Stage for Competitive M&A Battle

Market Chameleon (Tue, 4-Nov 9:28 AM)

Novo Nordisk’s Bid for Metsera Raises Major Antitrust Concerns: What’s at Stake?

Market Chameleon (Thu, 30-Oct 7:14 AM)